News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Taiwan court fined Tokyo Electron's Taiwan unit T$150 million and jailed five over stolen TSMC trade secrets, raising semiconductor supply-chain risk.
  • Pakistan mediators say Iran will resend an updated peace proposal within days after the U.S. rejected the prior draft.
  • Nucor shares hit an all-time high after Q1 revenue of $9.5 billion beat estimates, signaling stronger steel demand.
  • Universal Health Services shares fell 6.8% after Q1 results flagged exchange-enrollment headwinds and a $15 million exchange-related hit.
  • FedEx and UPS pledged to return U.S. tariff reimbursements to customers as the government begins processing refunds.
  • Blaize shares plunged after a short seller alleged its $50 million NeoTensr transaction may be fraudulent, prompting investor scrutiny.

Latest Articles

Team Inc Director Edward J. Stenger Buys $79,991 of Stock in Two Trades

Team Inc Director Edward J. Stenger Buys $79,991 of Stock in Two Trades

Edward J. Stenger, a director at Team Inc (NYSE:TISI), reported purchases totaling 5,000 shares valued at $79,991 in a Form 4 filing with the SEC. The trades occurred in two sessions on March 23 and March 24, 2026, at weighted average prices of $15.21 and $16.31 respectively. After these transactions, Stenger directly holds 14,890 shares. The purch…

Rigetti Computing Intends to Invest $100 Million in UK to Accelerate Quantum Computing Development

Rigetti Computing Intends to Invest $100 Million in UK to Accelerate Quantum Computing Development

Rigetti Computing announced plans to invest up to $100 million in the UK to accelerate quantum computing development, aiming to deploy a quantum computer with over 1,000 qubits within 3 to 4 years. This marks Rigetti's first major investment outside the US and aligns with the UK government's £2 billion quantum computing initiative. The company high…

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Minerva Neurosciences announced data from its open-label safety trial evaluating the co-administration of roluperidone and olanzapine. The study showed no significant safety, pharmacokinetic, or pharmacodynamic issues, supporting continued development. The company is now enrolling a confirmatory Phase 3 trial with topline data expected in the secon…

Firefly Aerospace Supports U.S. Space Force VICTUS DIEM Exercise

Firefly Aerospace Supports U.S. Space Force VICTUS DIEM Exercise

Firefly Aerospace, a U.S.-based space and defense technology company, supported Lockheed Martin and the U.S. Space Force in the VICTUS DIEM exercises focusing on rapid spacecraft processing and launch capabilities. The exercises demonstrated spacecraft arrival, integration, and launch operations within stringent timelines under simulated threat con…

WidePoint Reports Fourth Quarter and Full Year 2025 Financial Results

WidePoint Reports Fourth Quarter and Full Year 2025 Financial Results

WidePoint Corporation reported fourth quarter and full year 2025 results showing revenue growth compared to the prior year. The company achieved its 34th consecutive quarter of positive adjusted EBITDA and 9th quarter of positive free cash flow. Significant contract wins and backlog totaling over $220 million position WidePoint for future growth, p…

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

Artelo Biosciences announces strategic expansion of ART27.13 development targeting preservation of muscle mass in patients receiving GLP-1 receptor agonist therapy. Supported by clinical and preclinical data, patent filing, and initiation of new studies, the company aims to position ART27.13 as a differentiated companion therapy in the fast-growing…

Stran & Company Reports 40.6% Year-Over-Year Revenue Growth to $116.2 Million for the 2025 Fiscal Year

Stran & Company Reports 40.6% Year-Over-Year Revenue Growth to $116.2 Million for the 2025 Fiscal Year

Stran & Company, Inc. reported strong fiscal 2025 financial results with $116.2 million in sales, a 40.6% increase from 2024, and positive EBITDA of $0.2 million compared to a loss in the prior year. Revenue growth was driven by 12.9% organic growth in the core promotional products segment and a significant sales increase from the acquired Gander G…

Burke & Herbert Financial Services Corp. and LINKBANCORP, Inc. Announce Receipt of Shareholder Approval for Merger

Burke & Herbert Financial Services Corp. and LINKBANCORP, Inc. Announce Receipt of Shareholder Approval for Merger

Burke & Herbert Financial Services Corp. and LINKBANCORP, Inc., both Nasdaq-listed US community bank holding companies, have received shareholder approval to merge, with Burke & Herbert as the surviving entity. The merger aims to enhance financial solutions across multiple states in the Mid-Atlantic region and is subject to regulatory approvals and…

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

SeaStar Medical reported 2025 financial results highlighting significant progress in clinical trials for its Selective Cytopheretic Device (SCD) therapy for Acute Kidney Injury (AKI), expanding the QUELIMMUNE therapy's adoption in top pediatric hospitals, and preparing for FDA approvals. The company achieved over 50% enrollment in the pivotal NEUTR…

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights

Equillium, a clinical-stage biotech focused on immunobiology therapies for autoimmune and inflammatory diseases, reported Q4 and full year 2025 financial results. The company completed two financings totaling $85 million, bolstering cash reserves to $30.3 million as of year-end plus $35 million raised in March 2026, expected to fund operations thro…

Goodman and Luxor Capital Offload $175,945 in Meridian Holdings Stock

Goodman and Luxor Capital Offload $175,945 in Meridian Holdings Stock

Anthony Brian Goodman, a former director and former CEO of Meridian Holdings Inc./NV (NASDAQ: MRDN), together with Luxor Capital LLC (a greater-than-10% filing group), sold a combined 19,500 shares of the company’s common stock between March 17 and March 23, 2026, generating proceeds of $175,945. The trades occurred at prices reported between $8.54…

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Celcuity Inc. announced the FDA acceptance and priority review of its New Drug Application for gedatolisib targeting HR+/HER2-/PIK3CA wild-type advanced breast cancer with a PDUFA date of July 17, 2026. Positive Phase 3 trial results from the PIK3CA WT cohort showed significant improvement in progression-free survival and well-being measures. Topli…

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation reported a 10% revenue increase in FY2025 to $61.9 million, fueled by the successful launch and commercialization of Emrosi™, a treatment for rosacea. The company improved gross margins and achieved an adjusted EBITDA of $2.9 million, signaling financial strengthening despite a net loss of $11.4 million. Emrosi™ expanded…

Colliers Completes C$550 Million Senior Notes Issuance

Colliers Completes C$550 Million Senior Notes Issuance

Colliers International Group Inc. completed a private placement of C$550 million (approx. US$400 million) in 4.73% fixed rate senior unsecured notes due 2033. The funds will be used primarily for general corporate purposes, including repayment of borrowings under their revolving credit facility, enhancing financial flexibility to support long-term …